Granted Patent
B2
US 12,648,994 · App. 17/937,073 · Granted Jun 9, 2026
Methods of treating immune-mediated pulmonary injury with an anti-ILT7 antibody
Assignee:
Viela Bio, Inc.
A61K39/3955A61P11/00A61P31/14A61P31/20A61P37/06A61K2039/505A61K2039/54A61K2039/545C07K14/70503C07K16/2803C07K2317/21C07K2317/41
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.
Claims (27)
1 . A method for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject infected with a respiratory virus, the method comprising administering to the subject an anti-immunoglobulin-like transcript 7 (ILT7) antibody, thereby treating or preventing the IMPI, wherein the anti-ILT7 antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 1 and the light chain variable region (VL) of SEQ ID NO:2.
2 . The method of claim 1 , wherein the respiratory virus is selected from the group consisting of rhinovirus, adenovirus, influenza virus, respiratory syncytial virus, enterovirus D68, Severe Acute Respiratory Syndrome-coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome-coronavirus (MERS-COV), and Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-COV-2).
3 . The method of claim 2 , wherein the respiratory virus is SARS-CoV-2.
4 . The method of claim 3 , wherein the subject is a high-risk subject.
5 . The method of claim 4 , wherein the high-risk subject is a subject that is at least 60 years old, has a pre-existing respiratory condition or is immunocompromised.
6 . The method of claim 1 , wherein the respiratory virus is a coronavirus.
7 . The method of claim 6 , wherein, prior to the administering, the subject exhibited at least one symptom selected from the group consisting of: increased circulating levels of pro-inflammatory cytokines, increased local levels of pro-inflammatory cytokines, T-cell lymphopenia, and increased inflammatory markers.
8 . The method of claim 1 , wherein, prior to the administration, the subject exhibited at least one clinical marker of IMPI selected from the group consisting of: shortness of breath, hypoxia, abnormal chest imaging, and transaminitis.
9 . The method of claim 1 , wherein the anti-ILT7 antibody is daxdilimab.
10 . The method of claim 9 , wherein the administration reduces levels of circulating plasmacytoid dendritic cells (pDCs).
11 . The method of claim 10 , wherein the reduction of circulating pDCs is sustained for at least 15 days.
12 . The method of claim 1 , wherein the anti-ILT7 antibody is afucosylated.
13 . The method of claim 1 , wherein the anti-ILT7 antibody is administered at a dose of about 0.1 mg to about 1000 mg.
14 . The method of claim 13 , wherein the anti-ILT7 antibody is administered at a dose of about 5 mg to about 150 mg.
15 . The method of claim 1 , wherein the anti-ILT7 antibody is administered by subcutaneous injection.
16 . The method of claim 1 , further comprising administering a second therapy.
17 . The method of claim 16 , wherein the second therapy is selected from the group consisting of: remdesivir, a corticosteroid, an interleukin-6 (IL-6) inhibitor, an interleukin-2 (IL-2) inhibitor, a plasma transfusion, and a janus kinase (JAK) inhibitor.
18 . A method for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject infected with a respiratory virus, the method comprising administering an anti-immunoglobulin-like transcript 7 (ILT7) monoclonal antibody, thereby treating or preventing the IMPI, wherein the anti-ILT7 antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 1 and the light chain variable region (VL) of SEQ ID NO:2.
19 . The method of claim 18 , wherein the respiratory virus is selected from the group consisting of rhinovirus, adenovirus, influenza virus, respiratory syncytial virus, enterovirus D68, Severe Acute Respiratory Syndrome-coronavirus (SARS-COV), Middle Eastern Respiratory Syndrome-coronavirus (MERS-COV), and Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-COV-2).
20 . The method of claim 18 , wherein the subject is at high risk.
21 . The method of claim 20 , wherein the respiratory virus is Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-COV-2).
22 . The method of claim 18 , wherein the anti-ILT7 antibody is administered at a dose of about 0.1 mg to about 1000 mg.
23 . The method of claim 22 , wherein the anti-ILT7 antibody is administered at a dose of about 5 mg to about 150 mg.
24 . The method of claim 23 , wherein the anti-ILT7 antibody is administered at a dose of about 150 mg.
25 . The method of claim 18 , wherein the anti-ILT7 antibody is administered by subcutaneous injection.
26 . A method for treating a subject infected with a coronavirus, the method comprising administering an anti-immunoglobulin-like transcript 7 (ILT7) antibody, thereby treating the coronavirus infection or a symptom thereof, wherein the anti-ILT7 antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 1 and the light chain variable region (VL) of SEQ ID NO:2.
27 . The method of claim 26 , wherein the symptom is treated, and wherein the symptom is selected from the group consisting of: increased levels of a pro-inflammatory cytokine, T-cell lymphopenia, and increased levels of an inflammatory marker.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 3, 2022
From: ILLEI, GABOR; REES, WILLIAM; DRAPPA, JORN
To: VIELA BIO, INC.
Reel/Frame 061284/0952 →
Continuity (5)
Continuation
PCTUS2021025600
· Apr 2, 2021
Provisional Application
63066955
· Aug 18, 2020
Provisional Application
63052596
· Jul 16, 2020
Provisional Application
63004866
· Apr 3, 2020
References Cited (293)
US 4683195A
· Mullis et al.
· 1987
[cited by applicant]
US 4741900A
· Alvarez et al.
· 1988
[cited by applicant]
US 4873192A
· Kunkel
· 1989
[cited by applicant]
US 4885166A
· Meyer et al.
· 1989
[cited by applicant]
US 4902618A
· Berg
· 1990
[cited by applicant]
US 5116964A
· Capon et al.
· 1992
[cited by applicant]
US 5122464A
· Wilson et al.
· 1992
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5225538A
· Capon et al.
· 1993
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5314995A
· Fell, Jr. et al.
· 1994
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5427908A
· Dower et al.
· 1995
[cited by applicant]
US 5516637A
· Huang et al.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5580717A
· Dower et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5698426A
· Huse
· 1997
[cited by applicant]
US 5733743A
· Johnson et al.
· 1998
[cited by applicant]
US 5750753A
· Kimae et al.
· 1998
[cited by applicant]
US 5780225A
· Wigler et al.
· 1998
[cited by applicant]
US 5821047A
· Garrard et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5885793A
· Griffiths et al.
· 1999
[cited by applicant]
US 5892019A
· Schlom et al.
· 1999
[cited by applicant]
US 5939598A
· Kucherlapati et al.
· 1999
[cited by applicant]
US 5969108A
· McCafferty et al.
· 1999
[cited by applicant]
US 6172197B1
· McCafferty et al.
· 2001
[cited by applicant]
US 6180370B1
· Queen et al.
· 2001
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6521404B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6544731B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6555313B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6582915B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6593081B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6653068B2
· Frisch et al.
· 2003
[cited by applicant]
US 6706484B1
· Knappik et al.
· 2004
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7087726B2
· Chuntharapai et al.
· 2006
[cited by applicant]
US 7264963B1
· Knappik et al.
· 2007
[cited by applicant]
US 7619070B2
· Cardarelli et al.
· 2009
[cited by applicant]
US 7662381B2
· Cardarelli et al.
· 2010
[cited by applicant]
US 7741449B2
· Witte et al.
· 2010
[cited by applicant]
US 7888484B2
· Cardarelli et al.
· 2011
[cited by applicant]
US 8071323B2
· Dimitrov et al.
· 2011
[cited by applicant]
US 8084585B2
· Kamogawa et al.
· 2011
[cited by applicant]
US 8470992B2
· Kamogawa et al.
· 2013
[cited by applicant]
US 8605807B1
· Macrae
· 2013
[cited by applicant]
US 8758757B2
· Cardarelli et al.
· 2014
[cited by applicant]
US 8901036B2
· Willms et al.
· 2014
[cited by applicant]
US 8912624B2
· Kakehata
· 2014
[cited by applicant]
US 9114438B2
· Hoinkis et al.
· 2015
[cited by applicant]
US 9208495B2
· Altberg et al.
· 2015
[cited by applicant]
US 20020123057A1
· Zauderer et al.
· 2002
[cited by applicant]
US 20020146825A1
· Uhler
· 2002
[cited by applicant]
US 20030148316A1
· Lipford et al.
· 2003
[cited by applicant]
US 20040132101A1
· Lazar et al.
· 2004
[cited by applicant]
US 20070025992A1
· Takayama et al.
· 2007
[cited by applicant]
US 20080050340A1
· Kedl et al.
· 2008
[cited by applicant]
US 20090280128A1
· Kamogawa et al.
· 2009
[cited by applicant]
US 20100070346A1
· Davis
· 2010
[cited by applicant]
US 20110311558A1
· Cao et al.
· 2011
[cited by applicant]
US 20120135003A1
· Kamogawa et al.
· 2012
[cited by applicant]
US 20120316071A1
· Smider et al.
· 2012
[cited by applicant]
US 20130259872A1
· Kamogawa et al.
· 2013
[cited by applicant]
US 20130344509A1
· Nakamura et al.
· 2013
[cited by applicant]
US 20140056889A1
· Morimoto et al.
· 2014
[cited by applicant]
US 20150133317A1
· Robinson et al.
· 2015
[cited by applicant]
US 20160060326A1
· Zhou et al.
· 2016
[cited by applicant]
US 20160130343A1
· Kamogawa et al.
· 2016
[cited by applicant]
US 20170204179A1
· Kamogawa et al.
· 2017
[cited by applicant]
US 20200339673A1
· Vousden et al.
· 2020
[cited by applicant]
US 20200339682A1
· Kamogawa et al.
· 2020
[cited by applicant]
US 20220144940A1
· Vousden et al.
· 2022
[cited by applicant]
US 20220403020A1
· Rees et al.
· 2022
[cited by applicant]
US 20230250167A1
· Vousden et al.
· 2023
[cited by applicant]
US 20240287176A1
· Drappa
· 2024
[cited by applicant]
AU 2006328470A
· 2007
[cited by applicant]
AU 2012244391A1
· 2012
[cited by applicant]
CA 3017197A1
· 2017
[cited by applicant]
CN 1461310A
· 2003
[cited by applicant]
CN 104284903A
· 2015
[cited by applicant]
CN 104884049A
· 2015
[cited by applicant]
CN 105111311A
· 2015
[cited by applicant]
CN 109414499A
· 2022
[cited by applicant]
EP 0119476A2
· 1984
[cited by applicant]
EP 0396387A2
· 1990
[cited by applicant]
EP 1964852A1
· 2008
[cited by applicant]
JP 2019516392A
· 2019
[cited by applicant]
KR 20140053232A
· 2014
[cited by applicant]
RU 2431638C2
· 2011
[cited by applicant]
WO WO8403105A1
· 1984
[cited by applicant]
WO WO9002809A1
· 1990
[cited by applicant]
WO WO9110737A1
· 1991
[cited by applicant]
WO WO9201047A1
· 1992
[cited by applicant]
WO WO9218619A1
· 1992
[cited by applicant]
WO WO9311236A1
· 1993
[cited by applicant]
WO WO9515982A2
· 1995
[cited by applicant]
WO WO9520401A1
· 1995
[cited by applicant]
WO WO0127160A1
· 2001
[cited by applicant]
WO WO0158956A2
· 2001
[cited by applicant]
WO WO03012061A2
· 2003
[cited by applicant]
WO WO03100008A2
· 2003
[cited by applicant]
WO WO2004023973A2
· 2004
[cited by applicant]
WO WO2006013107A1
· 2006
[cited by applicant]
WO WO2006124269A2
· 2006
[cited by applicant]
WO WO2007072866A1
· 2007
[cited by applicant]
WO WO2009100309A2
· 2009
[cited by applicant]
WO WO2010065536A2
· 2010
[cited by applicant]
WO WO2011028933A1
· 2011
[cited by applicant]
WO 2012162367A1
· 2012
[cited by applicant]
WO WO2014036071A1
· 2014
[cited by applicant]
WO WO2016145307A1
· 2016
[cited by applicant]
WO WO2017156298A1
· 2017
[cited by applicant]
WO WO2018034784A1
· 2018
[cited by applicant]
WO WO2020023220A1
· 2020
[cited by applicant]
WO WO2021011716A1
· 2021
[cited by applicant]
WO WO2021011717A1
· 2021
[cited by applicant]
WO WO2021113702A1
· 2021
[cited by applicant]
WO WO2022098592A1
· 2022
[cited by applicant]
WO WO2022098593A1
· 2022
[cited by applicant]
WO WO2022192100A1
· 2022
[cited by applicant]
WO WO2022192308A1
· 2022
[cited by applicant]
WO WO2022203830A1
· 2022
[cited by applicant]
WO WO2022212227A1
· 2022
[cited by applicant]
WO WO2022235758A1
· 2022
[cited by applicant]
WO WO2023016888A1
· 2023
[cited by applicant]
WO WO2023016889A1
· 2023
[cited by applicant]
WO WO2023016893A1
· 2023
[cited by applicant]
WO WO2023016933A1
· 2023
[cited by applicant]
WO WO2024026388A1
· 2024
[cited by applicant]
WO 2024126431A1
· 2024
[cited by applicant]
Cao et al, 2010. Immunol Rev. 234(1), 22 pages as printed.
[cited by examiner]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only.
[cited by examiner]
Ferrara et al (2015. mAbs. 7(1): 32-41).
[cited by examiner]
Accession NP_036408, 2003, pp. 1-2.
[cited by applicant]
Niewold T., et al., “Targeting type I interferon in systemic lupus erythematosus” , Annals of the Rheumatic Diseases, vol. 12, May 26, 2016 (May 26, 2016), pp. 377-378.
[cited by applicant]
Viela B., “NCT03817424 A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis”…
[cited by applicant]
Accession P30273, 1993, pp. 1-2.
[cited by applicant]
Ames, R. S., et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,” Journal of Immunological Methods, Aug. 18, 1995, 184(2), pp. 177-186.
[cited by applicant]
Aruffo A., et al., “CD44 is the Principal Cell Surface Receptor for Hyaluronate,” Cell, Jun. 29, 1990, vol. 61 (7), pp. 1303-1313.
[cited by applicant]
Ashkenazi A., et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,” Proceedings of the National Academy of Sciences of the United States of America, Dec. 1991, vol. 88, pp. 1053…
[cited by applicant]
Asselin-Paturel C., et al., “Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody,” The Journal of Immunology USA, Dec. 2003, vol. 171, pp. 6466-6477, XP…
[cited by applicant]
Banham A.H., et al., “Identification of the CD85 Antigen as IL T2, an Inhibitory MHC Class I Receptor of the Immunoglobulin Superfamily,” Journal of Leukocyte Biology, Jun. 1999, vol. 65, pp. 841-845.
[cited by applicant]
Bianco P., et al., “Induction of Dendritic Cell Differentiation by IFN-alpha in Systemic Lupus Erythematosus,” Science, Nov. 16, 2001, vol. 294, pp. 1540-1543.
[cited by applicant]
Blasius A., et al., “A Cell-Surface Molecule Selectively Expressed on Murine Natural Interferon-Producing Cells that Blocks Secretion of Interferon-Alpha,” Blood, Jun. 1, 2004, vol. 103, No. 11, pp. 4201-4206.
[cited by applicant]
Brinkmann, U., et al., “Phage display of disulfide-stabilized Fv fragments,” Journal of Immunological Methods, May 11, 1995, 182(1), pp. 41-50.
[cited by applicant]
Burton D.R., et al., “Human Antibodies from Combinatorial Libraries,” Advances in Immunology, Jan. 1994, vol. 57, pp. 191-280.
[cited by applicant]
Butler J.E., “The Amplified ELISA: Principles of and Applications for the Comparative Quantitation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Separates,” Methods in E…
[cited by applicant]
Byrn R.A., et al., “Biological Properties of a CD4 Immunoadhesin,” Nature, Apr. 12, 1990, vol. 344, No. 6267, pp. 667-670.
[cited by applicant]
Cao W., et al., “Signaling and Ligand Interaction of ILT7: Receptor-Mediated Regulatory Mechanisms for Plasmacytoid Dendritic Cells,” Immunological Reviews, Mar. 2010, vol. 234, No. 1, pp. 163-176.
[cited by applicant]
Cao W., et al., “Plasmacytoid Dendritic Cell-Specific Receptor ILT7-FcεRIγ Inhibits Toll-Like Receptor-Induced Interferon Production,” Journal of Experimental Medicine, May 30, 2006, vol. 203, No. 6, pp. 1399-1405.
[cited by applicant]
Capon D.J., et al., “Designing CD4 Immunoadhesins for AIDS Therapy,” Nature, Feb. 9, 1989, vol. 337, pp. 525-531.
[cited by applicant]
Carrington M., et al., “The KIR Gene Cluster”, National Center of Biotechnology Information, May 28, 2003, 171 pages.
[cited by applicant]
Chapman A.P., “PEGylated Antibodies and Antibody Fragments for Improved Therapy: A Review,” Advanced Drug Delivery Reviews, Jun. 17, 2002, vol. 54, No. 4, pp. 531-545.
[cited by applicant]
Chen S., et al., “Ponatinib Protects Mice from Lethal Influenza Infection by Suppressing Cytokine Storm,” Frontiers in Immunology, Jun. 2019, vol. 10 (1393), pp. 1-13.
[cited by applicant]
Cho M., et al., “Sage Library Screening Reveals ILT7 as a Specific Plasmacytoid Dendritic Cell Marker That Regulates Type I IFNProduction,” International Immunology, Jan. 2008, vol. 20, No. 1, pp. 155-164.
[cited by applicant]
Chothia C., et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology, Aug. 20, 1987, vol. 196, No. 4, pp. 901-917.
[cited by applicant]
Cockett M.I., et al., “High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification,” Biotechnology, Jul. 1990, vol. 8, No. 7, pp. 662-667.
[cited by applicant]
Colbere-Garapin F., et al., “A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells,” Journal of Molecular Biology, Jul. 25, 1981, vol. 150 (1), pp. 1-14.
[cited by applicant]
Colman P. M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Biomolecular Research Institute, Jan. 1994, vol. 145, No. 1, pp. 33-36.
[cited by applicant]
Colonna M., et al., “A Family of Inhibitory and Activating Ig-Like Receptors that Modulate Function of Lymphoid and Myeloid Cells,” Seminars in Immunology, Apr. 2000, vol. 12, No. 2, pp. 121-127.
[cited by applicant]
Crouse G.F., et al., “Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes,” Molecular and Cellular Biology, Feb. 1983, vol. 3, No. 2, pp. 257-266.
[cited by applicant]
Dall'Acqua W.F., et al., “Antibody Humanization by Framework Shuffling,” Methods, May 2005, vol. 36, No. 1, pp. 43-60.
[cited by applicant]
Dashivets T., et al., “Oxidation in the Complementarity-Determining Regions Differentially Influences the Properties of Therapeutic Antibodies,” MABs, November- Dec. 2016, vol. 8, No. 8, pp. 1525-1535.
[cited by applicant]
Dayhoff M.O., et al., “A model of Evolutionary Change in Proteins”, Chapter 22 in Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC, 1978, vol. 5 (3), pp. 345-352.
[cited by applicant]
Dzionek A., et al., “BDCA-2, A Novel Plasmacytoid Dendritic Cell-specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon Alpha/beta Induction,” Journal of Experimental Medicine, …
[cited by applicant]
Edwards, B.M. et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” Journal of Molecular Biology, Nov. 14, 2003, 334(1, pp.…
[cited by applicant]
Foecking M.K., et al., “Powerful and Versatile Enhancer-Promoter Unit for Mammalian Expression Vectors,” Gene, Jan. 1986, vol. 45, No. 1, pp. 101-105.
[cited by applicant]
Foote J., et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” Journal of Molecular Biology, Mar. 20, 1992, vol. 224 (2), pp. 487-499.
[cited by applicant]
Gascoigne., et al., “Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein,” Proceedings of the National Academy of Sciences of the United States of America, May 1987, vol. 84, pp. 2936-2940.
[cited by applicant]
Gentz R., et al., “Bioassay for Trans-Activation Using Purified Human Immunodeficiency Virus Tat-Encoded Protein: Trans-Activation Requires mRNA Synthesis,” Proceedings of the National Academy of Sciences of the United …
[cited by applicant]
Hamers-Casterman C., et al., “Naturally Occurring Antibodies Devoid of Light Chains,” Nature, Jun. 3, 1993, vol. 363, No. 6428, pp. 446-448.
[cited by applicant]
Hoogenboom H.R., et al., “By-Passing Immunisation: Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, Sep. 20, 1992, vol. 227, No. 2, pp. 381-388.
[cited by applicant]
Hopkins S.J., et al., “Cytokines in Synovial Fluid: II. The Presence of Tumour Necrosis Factor and Interferon,” Clinical and Experimental Immunology, Jul. 1988, vol. 73, No. 1, pp. 88-92.
[cited by applicant]
“Horizon Therapeutics pic Announces New Development Programs at Virtual R&D Day,” Bloomberg, Sep. 29, 2021, 3 pages.
[cited by applicant]
Horizon Therapeutics Pic, Virtual R&D Day Presentation, Sep. 29, 2021, 118 pages.
[cited by applicant]
Horizon Therapeutics Pic, Virtual R&D Day Remarks, Sep. 29, 2021, 24 pages.
[cited by applicant]
Inouye S., et al., “Up-Promoter Mutations in the Lpp Gene of
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/025600, mailed Oct. 13, 2022, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/025600, mailed Oct. 5, 2021, 21 pages.
[cited by applicant]
Jalkanen M., et al., “Cell Surface Proteoglycan of Mouse Mammary Epithelial Cells is Shed by Cleavage of its Matrix-Binding Ectodomain from its Membrane-Associated Domain,” Journal of Cell Biology, Dec. 1987, vol. 105, …
[cited by applicant]
Jalkanen M., et al., “Heparan Sulfate Proteoglycans from Mouse Mammary Epithelial Cells: Localization on the Cell Surface with a Monoclonal Antibody,” Journal of Cell Biology, Sep. 1985, vol. 101 (3), pp. 976-984.
[cited by applicant]
Johnson et al., “Human Follicular Dendritic Cells a Study of Monoclonal Antibodies,” Clinical and Experimental Immunology, Apr. 1986, vol. 64 (1), pp. 205-213.
[cited by applicant]
Jones E.W., “Proteinase Mutants of
[cited by applicant]
Jones P.T., et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature, May 1986, vol. 321, pp. 522-525.
[cited by applicant]
Ju X-S., et al., “Immunoglobulin-like Transcripts ILT2, ILT3 and ILT7 Are Expressed by Human Dendritic Cells and Down-regulated Following Activation,” Gene, Apr. 28, 2004, vol. 331, pp. 159-164.
[cited by applicant]
Kameda Y., et al., “Production of a Monoclonal Antibody Against Cell-surface Glycoprotein of Guinea Pig Adrenocortical Cells,” The Journal of Histochemistry and Cytochemistry, Feb. 1993, vol. 41, No. 2, pp. 235-243.
[cited by applicant]
Kamogawa-Schifter Y., et al., “Ly49Q Defines 2 pDC Subsets in Mice,” Blood, Apr. 1, 2005, vol. 105, No. 7, pp. 2787-2792.
[cited by applicant]
Karnell et al., “Supplementary Materials for: Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus,” May 26, 2021, Science Translational …
[cited by applicant]
Karnell J.L., et al., “Depleting Plasmacytoid Dendritic Cells Reduces Local Type I Interferon Responses and Disease Activity in Patients With Cutaneous Lupus,” Science translational Medicine, May 26, 2021, vol. 13, No. …
[cited by applicant]
Kashihara M., et al., “A Monoclonal Antibody Specifically Reactive to Human Langerhans Cells,” The Journal of Investigative Dermatology, Nov. 1986, vol. 87, pp. 602-607.
[cited by applicant]
Ketileborough, C. A., et al., “Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments”, European Jou…
[cited by applicant]
Kingsman A.J., et al., “Replication in
[cited by applicant]
Klimka A., et al., “Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,” The British Journal of Cancer, Jul. 2000, vol. 83, No. 2, pp. 252-260.
[cited by applicant]
Kunkel T.A., et al., “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection,” Methods in Enzymology, 1987, vol. 154 pp. 367-382.
[cited by applicant]
Kunkel T.A., “Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection,” Proceedings of the National Academy of Sciences USA, Jan. 1985, vol. 82(2), pp. 488-492.
[cited by applicant]
Lefranc, M-P. et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, Jan. 2003, 27(Issue 1), pp. 55-77.
[cited by applicant]
Leong S.R., et al., “Adapting Pharmacokinetic Properties of a Humanized AntiInterleukin-8 Antibody for Therapeutic Applications using Site-Specific Pegylation,” Cytokine, Nov. 2001, vol. 16, No. 3, pp. 106-119.
[cited by applicant]
Lesslauer W., et al., “Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice from Lipopolysaccharide-Induced Lethality,” European Journal of Immunology, Nov. 1991, vol. 21, No. 11, pp. 2883-2886.
[cited by applicant]
Linsley P.S., et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” The Journal of Experimental Medicine, Mar. 1, 1991, vol. 173, No. 3, pp.…
[cited by applicant]
Linsley P.S. et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7,” The Journal of Experimental Medicine, Sep. 1991, vol. 174, pp. 561-569.
[cited by applicant]
Lloyd, C., et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design and Selection, Mar. 2009,…
[cited by applicant]
Lonberg N., et al., “Human Antibodies From Transgenic Mice,” International Reviews of Immunology, Jan. 1995, vol. 13, pp. 65-93.
[cited by applicant]
Lowy I., et al., “Isolation of Transforming DNA: Cloning the Hamster Aprt Gene,” Cell, Dec. 1980, vol. 22 (3), pp. 817-823.
[cited by applicant]
Mach H., et al., “Statistical Determination of the Average Values of the Extinction Coefficients of Tryptophan and Tyrosine in Native Proteins,” Analytical Biochemistry, Jan. 1992, vol. 200, No. 1, pp. 74-80.
[cited by applicant]
Maggio E.T., “Enzyme-Immunoassay,” CRC Press Incorporated, Nov. 1980, 30 Pages.
[cited by applicant]
Malleret B., et al., “Effect of SIVmac Infection on Plasmacytoid and CD1c+ Myeloid Dendritic Cells in Cynomolqus Macaques,” Immunology, Jun. 2008, vol. 124, pp. 223-233, DOI:10.1111/j.1365-2567.2007.02758.x.
[cited by applicant]
Marketos N., et al., “Type I Interferon Signature in Sjogren's Syndrome: Pathophysiological and Clinical Implications,” Clinical and Experimental Rheumatology, Jul. 4, 2019, vol. 37 (3), No. 118, pp. 185-191.
[cited by applicant]
Marks J.D., et al., “By-Passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage,” Journal of Molecular Biology, Dec. 1991, vol. 222, pp. 581-597.
[cited by applicant]
McCafferty J., et al., “Selection and Rapid Purification of Murine Antibody Fragments that Bind a Transition-State Analog by Phage Display,” Biotechnology and Applied Biochemistry, May-Jun. 1994, vol. 47, No. 2-3, pp. 1…
[cited by applicant]
Morgan R.A., et al., “Human Gene Therapy,” Annual Review of Biochemistry, Jul. 1993, vol. 62, pp. 191-217.
[cited by applicant]
Muller S., et al., “Spliceosomal Peptide P140 for Immunotherapy of Systemic Lupus Erythematosus: Results of an Early Phase II Clinical Trial,” Arthritis & Rheumatism, Dec. 2008, vol. 58, No. 12, pp. 3873-3883, DOI:10.10…
[cited by applicant]
Mulligan R.C., et al., “Selection for Animal Cells that Express the
[cited by applicant]
Mulligan R.C., “The Basic Science of Gene Therapy,” Science, May 14, 1993, vol. 260, No. 5110, pp. 926-932.
[cited by applicant]
Murphy et al., “Enhancing recombinant antibody performance by optimally engineering its format,” Journal of Immunological Methods, Dec. 2018, (463), pp. 127-133.
[cited by applicant]
Nakajima H., et al., “Cutting Edge: Human Myeloid Cells Express an Activating ILT Receptor (ILT1) That Associates with Fc Receptor gamma-Chain,” Journal of Immunology, Jan. 1, 1999, vol. 162, No. 1, pp. 5-8.
[cited by applicant]
Nelson P.N., et al., “Demystified Monoclonal Antibodies,” Journal of Clinical Pathology, Jun. 2000, vol. 53, pp. 111-117.
[cited by applicant]
Nestle F. O., et al., “Plasmacytoid Predendritic Cells Initiate Psoriasis Through Interferon-alpha Production,” Journal of Experimental Medicine, Jul. 4, 2005, vol. 202, No. 1, pp. 135-143.
[cited by applicant]
O'Hare K., et al., “Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase,” Proceedings of the National Academy of Sciences of the Unite…
[cited by applicant]
Ohtsuka M., et al., “NFAM1, an Immunoreceptor Tyrosine-Based Activation Motif-Bearing Molecule that Regulates B Cell Development and Signaling,” Proceedings of the National Academy of Sciences of the United States of Am…
[cited by applicant]
Orlando M., “Modification of Proteins and Low Molecular Weight Substances with Hydroxyethyl Starch (HES),” Inaugural Dissertation, Justus-Liebig-Universität Gießen, 2003, 191 pages.
[cited by applicant]
Osbourn J.K., et al., “Generation of a Panel of Related Human ScFv Antibodies With High Affinities for Human CEA”, Immunotechnology, Sep. 1996, 2(3), pp. 181-196.
[cited by applicant]
Paul W.E., “Structure and Function of Immunoglobulins,” Fundamental Immunology, 1993, 3rd Edition, Chapter 9, pp. 292-295.
[cited by applicant]
Peppel K., et al., “A Tumor Necrosis Factor (TNF) Receptor-Igg Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,” Journal of Experimental Medicine, Dec. 1, 1991, vol. 174 (6), pp. 1483-1489.
[cited by applicant]
Perez A., et al., “Myasthenia Gravis Induced by Alpha-Interferon Therapy,” American Journal of Hematology, Aug. 1995, vol. 49, No. 4, pp. 365-366.
[cited by applicant]
Persic, L., et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene, Mar. 10, 1997, 187(1), pp. 9-18.
[cited by applicant]
Presta L.G., “Antibody Engineering,” Current Opinion in Structural Biology, Aug. 1992, vol. 2 (4), pp. 593-596.
[cited by applicant]
Rattan S.I.S., et al., “Protein Synthesis, Posttranslational Modifications, and Aging,” Annals of the New York Academy of Sciences, Nov. 1992, vol. 663, pp. 48-62.
[cited by applicant]
Riechmann L., et al., “Reshaping Human Antibodies for Therapy,” Nature, Mar. 1988, vol. 332, No. 24, pp. 323-327.
[cited by applicant]
Rose N.R., “Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview,” American Journal of Epidemiology, vol. 183, No. 5, Mar. 1, 2016, pp. 403-406, DOI:10.1 093/aje/kwv292.
[cited by applicant]
Rothe C., et al., “The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity…
[cited by applicant]
Roux K.H., et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” The Journal of Immunology, Oct. 1998, vol. 161, pp. 4…
[cited by applicant]
Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences, USA, Mar. 1982, 79(6), pp. 1979-1983.
[cited by applicant]
Ruther U., et al., “Easy Identification of cDNA Clones,” The EMBO Journal, Jun. 27, 1983, vol. 2, No. 10, pp. 1791-1794.
[cited by applicant]
Safdari Y., et al., “Antibody Humanization Methods—A Review and Update,” Biotechnology and Genetic Engineering Reviews, Aug. 2013, vol. 29, No. 2, pp. 175-186.
[cited by applicant]
Santerre R.F., et al., “Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-Selection Markers in Mouse L Cells,” Gene, Oct. 1984, vol. 30, No. 1-3, pp. 147-156.
[cited by applicant]
Seifter S., et al., “Analysis for Protein Modifications and Nonprotein Cofactors,” Methods in Enzymology, Jan. 1990, vol. 182, pp. 626-646.
[cited by applicant]
Sheets M.D., et al., “Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens,” Proceedings of the National Academy of Scienc…
[cited by applicant]
Shiozawa S., et al., “Interferon-alpha in Lupus Psychosis,” Arthritis and Rheumatism, Apr. 1992, vol. 35, No. 4, pp. 417-422.
[cited by applicant]
Smith T.F., et al., “Comparison of Biosequences,” Advanced in Applied Mathematics, Dec. 1981, vol. 2, Issue 4, pp. 482-489.
[cited by applicant]
Stamenkovic I., et al., “The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and A2-6 Sialyltransferase, CD75, on B Cells,” Cell, Sep. 20, 1991, vol. 66, pp. 1133-1144.
[cited by applicant]
Stinchcomb D.T., et al., “Isolation and Characterisation of a Yeast Chromosomal Replicator,” Nature, Nov. 1, 1979, vol. 282, pp. 39-43.
[cited by applicant]
Szybalska E.H., et al., “Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait,” Proceedings of the National Academy of Sciences, USA, Oct. 15, 1962, vol. 48, No. 12, pp. 2026-20…
[cited by applicant]
Szymkowski, David E., “Creating the next generation of protein therapeutics through rational drug design,” Current Opinion Drug Discovery & Development, vol. 8, No. 5, Sep. 2005, pp. 590-600.
[cited by applicant]
Thorpe P.E., et al., “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates,” Immunological Reviews, Feb. 1982, vol. 62, pp. 119-158.
[cited by applicant]
Tolstoshev P., “Gene Therapy, Concepts, Current Trials and Future Directions,” Annual Review of Pharmacology and Toxicology, Apr. 1993, vol. 33, pp. 573-596, Retrieved from URL: www.annualreviews.org.
[cited by applicant]
Traunecker A., et al., “Highly Efficient Neutralization of HIV with Recombinant CD4-Immunoglobulin Molecules,” Nature, May 4, 1989, vol. 339(6219), pp. 68-70.
[cited by applicant]
Tschumper G., et al., “Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene,” Gene, Jul. 1980, vol. 10, No. 2, pp. 157-166.
[cited by applicant]
UNIPROT: “Leukocyte Immunoglobulin-Like Receptor Subfamily a Member 4,” UniProtKB-P59901, Oct. 3, 2003, 11 Pages.
[cited by applicant]
Vales-Gomez M., et al., “Genetic Variability of the Major Histocompatibility Complex Class I Homologue Encoded by Human Cytomegalovirus Leads to Differential Binding to the Inhibitory Receptor ILT2,” Journal of Virology…
[cited by applicant]
Van Heeke G., et al., “Expression of Human Asparagine Synthetase in
[cited by applicant]
Vaughan T.J., et al., “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library,” Nature Biotechnology, Mar. 1996, vol. 14, pp. 309-314.
[cited by applicant]
Verhoeyen M., et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, Mar. 25, 1988, vol. 239, No. 4847, pp. 1534-1536.
[cited by applicant]
Viela B., “A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases,” Clinical Trails, NCT02780674, May 23, 2016, Retrieved from URL: https://clinicaltrials.gov/ct2/show/NCT02780674.
[cited by applicant]
Wada M., et al., “Antithyroid Peroxidase Antibody and Development of Silent Thyroiditis during Interferon-alpha2a Treatment of Chronic Hepatitis C,” The American Journal of Gastroenterology, Aug. 1995, vol. 90, No. 8, p…
[cited by applicant]
Wang, Chunyan et al., “Preparation and Preliminary Identification of Anti-human ILT-4 Monoclonal Antibody,” Chinese Journal of Cellular and Molecular Immunology, 2008, vol. 24, No. 3, pp. 238-239 (English Abstract provi…
[cited by applicant]
Watson S.R., et al., “A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules,” Journal of Cell Biology, Jun. 1990, vol. 110, No. 6, pp. 2221-2229.
[cited by applicant]
Watson S.R., et al., “Neutrophil Influx into an Inflammatory Site Inhibited by a Soluble Homing Receptor-IgG Chimaera,” Nature, Jan. 1991, vol. 349, pp. 164-167.
[cited by applicant]
Weir A.N.C., et al., “Formatting Antibody Fragments to Mediate Specific Therapeutic Functions,” Biochemical Society Transactions, Aug. 1, 2002, vol. 30, Part. 4, pp. 512-516.
[cited by applicant]
Werth et al., “Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734,” [abstract]. Arthritis Rheumatology,…
[cited by applicant]
Werth et al., “Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734,” [presentation]. Arthritis Rheumatol…
[cited by applicant]
Wigler M., et al., “Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells,” Cell, May 1977, vol. 11, pp. 223-232.
[cited by applicant]
Wilson I.A., et al., “The Structure of an Antigenic Determinant in a Protein,” Cell, Jul. 1984, vol. 37, pp. 767-778.
[cited by applicant]
Wilson L.E., et al., “Autoimmune Disease Complicating Antiviral Therapy for Hepatitis C Virus Infection,” Seminars in Arthritis and Rheumatism, Dec. 2002, vol. 32, No. 3, pp. 163-173.
[cited by applicant]
Wu et al., “An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Antibody Complementarity,” Journal of Experimental Medicine, Mar. 1970, vol. 1…
[cited by applicant]
Wu G.Y., et al., “Delivery Systems for Gene Therapy,” Biotherapy, Jan. 1991, vol. 3, pp. 87-95.
[cited by applicant]
Young N.T., et al., “Conserved Organization of the ILT/LIR Gene Family Within the Polymorphic Human Leukocyte Receptor Complex,” Immunogenetics, May-Jun. 2001, vol. 53, No. 4, pp. 270-278.
[cited by applicant]
Zettlmeissl G., et al., “Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins,” DNA and Cell Biology, Jun. 1990, vol. 9, No. 5, pp. 347-353.
[cited by applicant]
Zurfluh L.L., “Auxin-Induced Changes in the Patterns of Protein Synthesis in Soybean Hypocotyl,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 1980, vol. 77, No. 1, pp. 357-361.
[cited by applicant]
Amodio G. et al., Dendritic cells: a double-edge sword in autoimmune responses. Front Immunol, vol. 3, No. 233, pp. 1-9 (2012).
[cited by applicant]
Belousov U. V., Gurevich K. G. “Clinic pharmacokinetics,” Drug dosing practice: Special edition of Series Rational pharmacotherapy, M.: Literra, 288 sh., (2005).
[cited by applicant]
Davison et al., “New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production”, J Clin Cell Immunol, 8(6), doi:10.4172/2155-9899.1000534, (2017).
[cited by applicant]
Ito, Plasmacytoid Dendritic cells and type I interferon as therapeutic cellular and molecular targets of autoimmune diseases, Cytometry Research 22 (1), pp. 37-46 (2012).
[cited by applicant]
Mould D. R. et al. “Pharmacokinetics and pharmacodynamics of monoclonal antibodies,” BioDrugs, vol. 24, No. 1, p. 23-39 (2010).
[cited by applicant]
Skarlis C. et al. “Biologics in Sjogren's syndrome,” Pharmacological Research. vol. 147, Art. No. 104389, (2019).
[cited by applicant]
Tyagi R., Gupta Ì. N. “Use of c chemical modification and chemical cross-linking for stabilizing proteins (enzymes),” Biochemistry, vol. 63, N. 3., Edition 3, pp. 395-407 (1998).
[cited by applicant]
Accession No. AF041261, 1999, pp. 1-2.
[cited by applicant]
Olsen et al., “Alopecia areata investigational assessment guidelines—Part II. National Alopecia Areata Foundation”, J Am Acad Dermatol. Sep. 2004; 51(3): 440-447.
[cited by applicant]
Olsen et al., “Salt II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss”. J Am Acad Dermatol. Dec. 2016; 75(6): 1268-1270.
[cited by applicant]
Olsen et al., “Objective outcome measures: Collecting meaningful data on alopecia areata”. J Am Acad Dermatol. Sep. 2018; 79(3): 470-478.e3.
[cited by applicant]
Stroop S.D., et al., “Photosensitizers form in Histidine Buffer and Mediate the Photodegradation of a Monoclonal Antibody,” Journal of Pharmaceutical Sciences, vol. 100, No. 12, Dec. 2011, pp. 5142-5155.
[cited by applicant]
Cao et al., “Regulation of TLR 7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction”, J Exp. Med. 206(7), pp. 1603-1614 (2009).
[cited by applicant]
Greiff et al., “Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice”, BMC Immunology, vol. 15, pp. 1-14 (2014).
[cited by applicant]
Janeway et al., “The generation of diversity in immunoglobulins”, Immunobiology, 5th edition, New York: Garland Science (2001).
[cited by applicant]
Lamot et al., “Methods for Type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases”, Clinical and Experimental Rheumatology, vol. 37(6), pp. 1077-1083 (2019).
[cited by applicant]
Palma et al., “Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity”, Biochimica et Biophysica Acta, 1826(2), pp. 407-414 (2012).
[cited by applicant]
Rabia et al., “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility”, Biochemical Engineering Journal, vol. 137, pp. 365-374 (2018).
[cited by applicant]